First new asthma treatment in a decade


There is new hope for those with “difficult to treat” asthma in the new year, with breakthrough biologic to be PBS listed on 1 Jan Nucala (mepolizumab) is the first therapy to be approved as an add-on treatment for with severe refractory eosinophilic asthma. Similar to Novartis’ Xolair (omalizumab), GSK’s Nucala (mepolizumab) is designed to

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous The week in review
Next Holiday wishes from the King Review Panel